|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
BCA-225 staining was observed in 74 cases (64.3%); however this latter marker lacks also specificity owing to the reported widespread staining in other malignancies.
|
28470571 |
2018 |
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In the mouse, the downstream signaling molecules SLP-65 and Btk cooperate to limit proliferation and induce differentiation of pre-B cells, thereby acting as tumor suppressors to prevent pre-B cell leukemia.
|
16300960 |
2006 |
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, the somatic loss of SLP-65 and the accompanying block in pre-B-cell differentiation might be one of the primary causes of childhood pre-B ALL.
|
12761551 |
2003 |
|
Lymphoma
|
0.020 |
Biomarker
|
group |
BEFREE |
Based on these findings, we investigated (i.) whether SLP65-deficiency also occurs in mature B cell-derived lymphoma and (ii.) whether SLP65-deficient B cell lymphoma cells use an alternative B cell receptor signaling pathway in the absence of SLP65.
|
16568084 |
2006 |
|
B-Cell Lymphomas
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Moreover, we observed consistent expression of phosphorylated BLNK, an activated BCR adaptor protein, in human B cell lymphomas.
|
17717600 |
2007 |
|
B-Cell Lymphomas
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Indeed, expression of SLP65 protein was also missing in a fraction of B cell lymphoma cases.
|
16568084 |
2006 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
These results suggest that BCA is a good drug candidate for cancer therapy.
|
14660655 |
2004 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
These results suggest that BCA-5 has antiangiogenic properties and should be considered a potent antiangiogenesis drug for the treatment of cancer.
|
30335638 |
2018 |
|
Congenital Abnormality
|
0.010 |
Biomarker
|
group |
BEFREE |
Superselective transvenous embolization with Onyx and n-BCA for vein of Galen aneurysmal malformations with restricted transarterial access: safety, efficacy, and technical aspects.
|
28689342 |
2017 |
|
Alzheimer's Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
<b>Abbreviation used:</b> Aβ25-35: Amyloid-β 25-35; AD: Alzheimer's disease; BCA: Bicinchoninic acid; GSH: glutathione; PBS: Phosphate buffered solution; SDS: Sodium dodecylsulphate; SOD: Superoxide dismutase.
|
28216895 |
2019 |
|
Congenital arteriovenous malformation
|
0.010 |
Biomarker
|
disease |
BEFREE |
N-BCA injection into AVM can result in premature distal migration or early precipitation and reflux into the feeder vessels.
|
30851033 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, the data suggest that AT1R, AT2R or Mas could be used as a diagnostic marker of BCa and AT2R is a promising novel target gene for BCa gene therapy.
|
28599664 |
2017 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, the data suggest that AT1R, AT2R or Mas could be used as a diagnostic marker of BCa and AT2R is a promising novel target gene for BCa gene therapy.
|
28599664 |
2017 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
When p53-mutated cancer cell lines (MDA-MB-231 breast cancer cell and SW620 colon cancer cell) were treated with 10 microM HCA or BCA, it induced growth arrest and apoptosis of tumor cells.
|
14660655 |
2004 |
|
Dermatitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This is the first description of an enteroviral infection associated arthritis and dermatitis in a patient with BLNK deficiency.
|
25893637 |
2015 |
|
Enterovirus Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
This is the first description of an enteroviral infection associated arthritis and dermatitis in a patient with BLNK deficiency.
|
25893637 |
2015 |
|
IGA Glomerulonephritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Increase in B-cell-activation factor (BAFF) and IFN-gamma productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CpG-ODN) in patients with IgA nephropathy.
|
18249037 |
2008 |
|
leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Reconstitution of SLP65 expression in SLP65-deficient leukemia and lymphoma cells results in downregulation of RAG1/2 expression and prevents both de novo V(H)-DJ(H) rearrangements and secondary V(H) replacement.
|
16636677 |
2006 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further study found that CD5 and BLNK coexpressed in CLL, but not in normal B- or T cells, are required for STAT3 phosphorylation.
|
28130399 |
2017 |
|
Lymphoid leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells.
|
16636677 |
2006 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results indicate that BLNK deficiency is a rare occurrence in childhood B-lineage ALL and is unlikely to be a common leukemogenic event as previously proposed.
|
15029213 |
2004 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.010 |
Biomarker
|
disease |
BEFREE |
B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.
|
26703467 |
2016 |
|
Waldenstrom Macroglobulinemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, three of the target genes activated by PAX5 - CD79, BLNK and SYK - were upregulated in WM-PC.
|
17252022 |
2007 |
|
Parasitic Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In groupers infected with Cryptocaryon irritans, EcBLNK was regulated in the infected sites and the systemic organ which suggests that EcBLNK was activated in the immune response to parasite infection.
|
30055251 |
2018 |
|
Protein Deficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
Enteroviral Infection in a Patient with BLNK Adaptor Protein Deficiency.
|
25893637 |
2015 |